EGFR and non-small cell lung carcinoma: However, EGFR overexpression is observed in various cancers, including head and neck tumors, non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer, ovarian cancer, prostate cancer, renal cancer and glioblastoma, with a notably higher positivity rate in patients with low differentiation or metastasis (Liu et al., 2020; Nair et al., 2022; Uribe et al., 2021).